GILUPI Announces Attendance and Exhibition at the ACTC Conference 2019
GILUPI GmbH announced today that the company is a sponsor of the 4th ACTC “Liquid Biopsy: Latest Advances and Future Challenges” meeting. The conference is held in Corfu, Greece from October 2nd to 5th 2019.
(firmenpresse) - The main aim of the meeting is to bring together researchers from academia, clinics and industry to present, discuss and share the latest information on liquid biopsy. State-of-the-art research on the latest technical advancements in the isolation and molecular characterization of CTCs, ctDNA, miRNAs and exosomes will be presented in selected oral presentations and poster sessions.
Results generated with the GILUPI CellCollector® are presented by several research groups throughout the meeting. For example, a presentation entitled ‘Combination of in vivo CTC isolation and in situ Padlock probe technology for mRNA detection’ will be presented by researchers from the Center for Biomarker Research in Medicine (CBmed), Graz, the University Clinic Halle, Germany and the Gottfried Schatz Research Center at the Medical University Graz.
”We are proud to be a sponsor of this important scientific meeting and are looking forward to discussing the latest clinical studies and developments in CTC research with some of the leading experts in the field of liquid biopsy.” commented Dr. Christian Jurinke, CEO of GILUPI GmbH.
GILUPI will have a booth in the exhibition area to interact with the attendees and scientists will be available for questions and discussions during the exhibition hours.
Unternehmensinformation / Kurzprofil:
About GILUPI
GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus is the diagnostics market for cancer.
The concept of personalized medicine becomes increasingly important in oncology. The identification of the right drug for the individual patient is todays challenge in clinical practice. To address this medical need, the GILUPI CellCollector® is used to enrich rare cells by immuno-capture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers in various cancer types. Isolated cells can be characterized and analyzed down to a molecular level with immunostaining, DNA- or RNA-based methods.
The GILUPI CellCollector® is the first in vivo CTC isolation product that is CE approved.
For further information visit www.gilupi.com
Datum: 19.09.2019 - 15:27 Uhr
Sprache: Deutsch
News-ID 599141
Anzahl Zeichen: 1531
contact information:
Contact person: Dr. Christian Jurinke
Town:
Potsdam
Phone: +4933158184781
Kategorie:
Healthcare & Medical
Typ of Press Release: Tradeshow
type of sending: send
Date of sending: 19.09.2019
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"GILUPI Announces Attendance and Exhibition at the ACTC Conference 2019"
steht unter der journalistisch-redaktionellen Verantwortung von
GILUPI GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
